KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Depreciation & Amortization (CF) (2017 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Depreciation & Amortization (CF) for 9 consecutive years, with $260.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) fell 3.35% year-over-year to $260.0 million, compared with a TTM value of $1.0 billion through Dec 2025, down 5.38%, and an annual FY2025 reading of $1.0 billion, down 5.38% over the prior year.
  • Depreciation & Amortization (CF) was $260.0 million for Q4 2025 at Teva Pharmaceutical Industries, up from $247.0 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $376.0 million in Q1 2021 and bottomed at $244.0 million in Q1 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $292.6 million, with a median of $291.5 million recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) dropped 20.16% in 2021, then rose 17.38% in 2022.
  • Year by year, Depreciation & Amortization (CF) stood at $320.0 million in 2021, then dropped by 4.38% to $306.0 million in 2022, then fell by 13.07% to $266.0 million in 2023, then increased by 1.13% to $269.0 million in 2024, then dropped by 3.35% to $260.0 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for TEVA at $260.0 million in Q4 2025, $247.0 million in Q3 2025, and $251.0 million in Q2 2025.